Table 2. Summary of findings.
| Outcomes | Effect size [95% CI] | Heterogeneity (I2)/% | Number of participants | Quality of evidence (GRADE) | TSAb |
|---|---|---|---|---|---|
| ΔHSDS | WMD 0.38 [0.07, 0.68] | 76 | 528 | High | Efficacy area |
| ΔHSDS at 1 year post-withdrawal | WMD 0.22 [0.10, 0.35] | 19 | 528 | High | Efficacy area |
| ΔHSDS over 1 year post-withdrawal | WMD 0.38 [-0.13, 0.88] | 79 | 366 | Moderate | Not reached |
| ΔHSDS in prepubertal | WMD 0.60 [0.21, 0.98] | 0 | 171 | High | Efficacy area |
| ΔHSDS in prepubertal at 1 year post-withdrawal | WMD 0.39 [0.16, 0.63] | 0 | 171 | High | Efficacy area |
| ΔHSDS in pubertal | WMD 0.09 [-0.33, 0.51] | 12 | 116 | High | Not reached |
| AR | RR 1.04 [0.80, 1.36] | 44 | 528 | High | Futility area |
| AR at 1 year post-withdrawal | RR 1.12 [0.80, 1.56] | 0 | 528 | High | Futility area |
| AR over 1 year post-withdrawal | RR 1.20 [0.89, 1.60] | 30 | 366 | High | Not reached |
| eGFR at 6 months post-withdrawal | WMD -0.09 [-7.38, 7.20] | 0 | 236 | High | Futility area |
| eGFR at 1 year post-withdrawal | WMD -3.56 [-9.97, 2.86] | 6 | 302 | High | Required information size |
| eGFR at 2 years post-withdrawal | WMD -0.93 [-11.20, 9.34] | 0 | 170 | High | Futility area |
| NODAT | RR 0.31 [0.13, 0.75] | 0 | 326 | High | Not reached |
| Hypertension | RR 0.64 [0.46, 0.88] | 0 | 326 | High | Not reached |
| Infectiona | RR 1.09 [0.93, 1.28] | 0 | 326 | High | Not reached |
| CMV infection | RR 1.42 [0.88, 2.31] | 0 | 326 | Moderate | Not reached |
| PTLD | RR 1.64 [0.43, 6.25] | 47 | 458 | Moderate | Not reached |
| DGF | RR 1.46 [0.29, 7.41] | 55 | 326 | Low | Not reached |
| Anaemia | RR 1.79 [0.87, 3.69] | 63 | 326 | Low | Not reached |
a. Comparison of the risk of at least one type of infection.
b. If the cumulative Z curve did not cross the required information size but it crossed the efficacy boundary, then the outcome reached the efficacy area. If the cumulative Z curve did not cross the required information size but it crossed the futility boundary, then the outcome reached the futility area. If the cumulative Z curve crossed neither the required information size nor the efficacy and futility boundary, then the outcome was considered not reached.
CI, confidence interval; TSA, trial sequential analysis; HSDS, height standard deviation score; WMD, weighted mean difference; AR, acute rejection; RR, relative risk; eGFR, estimated glomerular filtration rate; NODAT, new-onset diabetes after transplant; PTLDs, post-transplant lymphoproliferative disorders; DGF, delayed graft function.